Publisher
Springer Nature Singapore
Reference6 articles.
1. Australian Institute of Health and Welfare. Cancer in Australia: an overview in 2014. CAN 88. Canberra: Australian Institute of Health and Welfare; 2014. Available https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-rankings-data-visualisation. Accessed May 2023.
2. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.
3. Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood E. Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. The myeloma landscape in Australia and New Zealand: the first 8 years of the myeloma and related diseases registry (MRDR). Clin Lymphoma Myeloma Leuk. 2021;21(6):e510–20. https://doi.org/10.1016/j.clml.2021.01.016. Epub 2021 Jan 30. PMID: 33785297.
4. Creeper K, Augustson B, Kusel K, Fulham MJ, Ho J, Quach H, Mollee P, Weber N, Talaulikar D, Johnston A, Murphy N, Joshua D, Ward C, Ling S, Gibson J, Szer J, Harrison S, Zannettino A, Jaksic W, Lee C, Spencer A, Kalff A, Szabo F, Romeril K, Chan H, Gibbs S, Horvath N, Prince HM. Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Intern Med J. 2021;51:1707–12. https://doi.org/10.1111/imj.15457.
5. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.